US2017071911A1PendingUtilityA1
Pharmaceutical composition for external use
Est. expiryMar 8, 2026(expired)· nominal 20-yr term from priority
A61P 31/10A61P 31/02A61P 17/00A61K 31/167A61K 47/22C07D 409/06A61K 9/08A61K 31/4178A61K 31/4015A61K 47/18A61K 9/0014A61K 31/385
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) N-methyl-2-pyrrolidone. (−)-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A pharmaceutical composition for external use, comprising:
i) (R)-luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) N-methyl-2-pyrrolidone at a concentration of 0.1 to 40% by mass.
(−)-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile
2 . A pharmaceutical composition according to claim 1 , wherein the composition comprises N-methyl-2-pyrrolidone in an amount of 1 to 10% by mass of the composition.
3 . A pharmaceutical composition according to claim 1 , wherein the composition comprises (R)-luliconazole in an amount of 0.5 to 15% by mass of the composition.
4 . A pharmaceutical composition according to claim 1 , wherein the composition further comprises ethanol.
5 . A pharmaceutical composition according to claim 4 , wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition.
6 . A method of treating mycotic disease comprising externally administering the composition of claim 1 to an individual in need of treatment.
7 . A method according to claim 6 , wherein the mycotic disease is foot trichophytosis, trichophytosis corporis or trichophytosis on a hard keratin portion.
8 . A method according to claim 6 , wherein the mycotic disease is athlete's foot.
9 . A method according to claim 6 , wherein the mycotic disease is onychomycosis.
10 . A method according to claim 6 , wherein the mycotic disease is a mycotic disease of a nail.
11 . A method according to claim 6 , wherein the mycotic disease is dermatomycosis.
12 . A pharmaceutical composition according to claim 2 , wherein the composition comprises (R)-luliconazole in an amount of 0.5 to 15% by mass of the composition.
13 . A pharmaceutical composition according to claim 2 , wherein the composition further comprises ethanol.
14 . A pharmaceutical composition according to claim 13 , wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition.
15 . A pharmaceutical composition according to claim 3 , wherein the composition further comprises ethanol.
16 . A pharmaceutical composition according to claim 15 , wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition.
17 . A pharmaceutical composition according to claim 12 , wherein the composition further comprises ethanol.
18 . A pharmaceutical composition according to claim 17 , wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition.
19 . A pharmaceutical composition for external use, consisting essentially of:
i) (R)-(−)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile and/or a salt thereof; and ii) N-methyl-2-pyrrolidone at a concentration of 0.1 to 40% by mass.
20 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a lotion.Join the waitlist — get patent alerts
Track US2017071911A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.